LONDON, March 25, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Investor-Edge has initiated coverage on the following equities: Zoetis Inc. (NYSE: ZTS), Horizon Pharma PLC (NASDAQ: HZNP), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Actavis PLC (NYSE: ACT), and The Medicines Company (NASDAQ: MDCO). Free research report on Zoetis can be accessed at http://get.Investor-Edge.com/pdf/?c=Zoetis&d=25-Mar-2015&s=ZTS. On Tuesday, March 24, 2015, the NASDAQ Composite ended at 4994.73, down 0.32%, the Dow Jones Industrial Average declined 0.58%, to finish the day at 18,011.14, and the S&P 500 closed at 2,091.50, down 0.61%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 856.55, down 0.86%, while the index has advanced 7.75% in the previous three months. Register for your complimentary reports at the links given below.
On Tuesday, shares in Zoetis Inc. fluctuated between $46.76 and $47.61 before ending the session 0.28% lower at $47.02. The stock reported a trading volume of 1.94 million shares, below its three months average volume of 3.32 million shares. Shares of the company traded at a PE ratio of 33.41. Zoetis Inc.'s shares have advanced 3.57% in the last one month, 7.25% in the previous three months and 61.36% in the past one year. The stock is trading above its 50-day and 200-day moving averages of $45.09 and $39.04, respectively. Moreover, shares of Zoetis Inc. have a Relative Strength Index (RSI) of 58.88. Sign up and read the free notes on ZTS at:
http://get.Investor-Edge.com/pdf/?c=Zoetis&d=25-Mar-2015&s=ZTS
Horizon Pharma PLC's stock edged 0.54% lower, to close the day at $22.02. The stock recorded a trading volume of 1.59 million shares, below its three months average volume of 2.53 million shares. The stock oscillated between $21.89 and $22.46 during the session. Over the last one month and over the past three months, Horizon Pharma PLC's shares have surged 18.96% and 77.87%, respectively. Further, the stock has gained 40.70% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. The stock's 50-day moving average of $18.27 is above its 200-day moving average of $13.94. Additionally, Horizon Pharma PLC traded at a PE ratio of 439.56 and has an RSI of 65.99. The complimentary notes on HZNP can be downloaded as in PDF format at:
http://get.Investor-Edge.com/pdf/?c=Horizon%20Pharma&d=25-Mar-2015&s=HZNP
On Tuesday, shares in Valeant Pharmaceuticals International Inc. recorded a trading volume of 1.27 million shares, lower than its three months average volume of 3.14 million shares. The stock ended the day at $203.11, which was 0.27% below its previous day's closing of $203.67, and registered an intraday range of $202.40 and $206.00. Shares of the company traded at a PE ratio of 77.56. Valeant Pharmaceuticals International Inc.'s shares have advanced 0.55% in the last one month, 44.74% in the previous three months and 54.49% in the past one year. The stock is trading above its 50-day and 200-day moving averages of $177.88 and $139.75, respectively. Furthermore, shares of Valeant Pharmaceuticals International Inc. have an RSI of 63.91. Register for free on Investor-Edge and access the latest research on VRX at:
http://get.Investor-Edge.com/pdf/?c=Valeant%20Pharma%20Intl.&d=25-Mar-2015&s=VRX
Actavis PLC's stock lost 1.85%, to close Tuesday's session at $309.13, after oscillating between $308.92 and $316.93. The stock recorded a trading volume of 3.27 million shares, above its three months average volume of 3.13 million shares. Over the last one month and the previous three months, Actavis PLC's shares have advanced 6.92% and 21.61%, respectively. Additionally, the stock has surged 49.85% in the last one year. The company's shares are trading above their 50-day and 200-day moving averages. The stock's 50-day moving average of $285.38 is above its 200-day moving average of $247.80. Further, Actavis PLC's stock traded at a PE ratio of 125.86 and has an RSI of 70.86. The complete research on ACT is available for free at:
http://get.Investor-Edge.com/pdf/?c=Actavis&d=25-Mar-2015&s=ACT
The Medicines Co.'s stock finished Tuesday's session 1.03% lower at $30.16. A total of 1.27 million shares were traded, which was close to its three months average volume of 1.31 million shares. The stock moved between $30.07 and $30.91 during the session. The Medicines Co.'s shares have gained 4.13% in the last one month and 11.44% in the previous three months. Additionally, the stock has gained 3.20% in the past one year. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $28.29 is greater than its 200-day moving average of $26.19. The Medicines Co.'s stock has an RSI of 59.58. Free in depth research on MDCO is available at:
http://get.Investor-Edge.com/pdf/?c=Medicines&d=25-Mar-2015&s=MDCO
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
